Transplante de Melanocitos y Queratinocitos demostró beneficio en leucodermias.

MKTP Procedure Satisfactory for Leukoderma Treatment

J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al

May 24, 2017

The melanocyte-keratinocyte transplantation procedure (MKTP) provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma, according to a recent study. Furthermore, MKTP can maintain repigmentation for at least 72 months. Researchers performed a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014. Repigmentation was assessed by a 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI). They found:

• 100 patients had MKTP performed at 236 anatomically-based lesions (ABLs); 63 patients with 157 ABLs had long-term data available (12-72 months; median, 24 months).
• Segmental vitiligo, nonsegmental vitiligo, and physical leukoderma demonstrated improvement in VASI scores: −75.6 ± 24.6%, −59.2 ± 36.6%, and −32.4 ± 33.5%, respectively.
• In vitiligo, at 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of ABLs, respectively, maintained >75% repigmentation.
• Skin phototype, age, and anatomic location of ABLs had no significant effect on the outcome of treatment.

Citation:

Silpa-Archa N, Griffith JL, Huggins RH, et al. Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas. [Published online ahead of print May 11, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.01.056.